- FDA approves Par's generic bupropion hydrochloride extended-release tablets
- Crossmark names Janet Carter-Smith VP
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- FDA approves Mylan antidepressant after company reaffirms efficacy
NOIDA, India — The Food and Drug Administration has approved drugs for depression and smoking cessation made by Jubilant Life Sciences, the company said.
Jubilant, based in India, announced the approval of generic bupropion hydrochloride extended-release tablets in the 100-mg, 150-mg and 200-mg strengths, and another bupropion hydrochloride extended-release tablet product in the 150-mg strength.
The first product is a generic version of GlaxoSmithKline's antidepressant Wellbutrin SR, while the second is a version of GSK's anti-smoking drug Zyban.
The total sales of the products per year are $518 million, according to IMS Health. Jubiliant will launch them next year.